After surgery in stage III colorectal cancer, doctors checked ctDNA — a blood test for leftover cancer. The test is called Signatera. If ctDNA is detected, these patients have a more poor outcome which represented about 20% of people in the study. If ctDNA was positive, patients who added 400mg celebrex (a common anti-inflammatory) daily had double the chance of staying cancer-free compared to chemo alone.” In those who were ctDNA-negative patients (i.e. not detected)? Almost no extra benefit. How often are patients offered a personalized approach for CtDNA testing in stage III Colorectal Cancer? The addition of Celebrex to standard chemo appears to improve survival in these patients and should be explored. These tests are available privately here in BC.
https://www.facebook.com/reel/1594168465009896
https://www.instagram.com/p/DY5n4W0scFe/
https://youtube.com/shorts/SN9h9hrgatE?si=PPcmIQ9K5sPeH3mU
https://pmc.ncbi.nlm.nih.gov/articles/pmid/41343176/
Discuss what this means for you
Research can raise useful questions. A study or individual case report does not establish that a treatment is suitable for everyone. Discuss medications, supplements and treatment changes with your care team.
Talk with our team